Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
The subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.
Trial Details
- NCT ID
- NCT07742332
- Phase
- PHASE2
- Sponsor
- Peng Zhang
- Status
- RECRUITING
- Cancer Type
- Lung Cancer
- Interventions
- Fumetinib combined platinum-based double chemotherapy
- Concurrent Radiochemotherapy
- Locations (sample)
- Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
- NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy;
- At stage II-IIIA (TNM Staging, Version 8) as identified by chest CT, PET-CT or/and EBUS;
- No systemic metastasis (confirmed by head MRI, whole body bone scan, PET-CT, liver and adrenal CT, etc.);
- With the feasibility to receive radical surgery ;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →